Tumor Vessel Normalization and Immunotherapy in Gastric Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2022 Jul 25

PMID 35872968

Authors

Xianzhe Yu

Shan He

Jian Shen

Qiushi Huang

Peng Yang

Lin Huang

Dan Pu

Li Wang

Lu Li

Jinghua Liu

Zelong Liu

Lingling Zhu

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is a common malignant tumor, and patients with GC have a low survival rate due to limited effective treatment methods. Angiogenesis and immune evasion are two key processes in GC progression, and they act synergistically to promote tumor progression. Tumor vascular normalization has been shown to improve the efficacy of cancer immunotherapy, which in turn may be improved through enhanced immune stimulation. Therefore, it may be interesting to identify synergies between immunomodulatory agents and anti-angiogenic therapies in GC. This strategy aims to normalize the tumor microenvironment through the action of the anti-vascular endothelial growth factor while stimulating the immune response through immunotherapy and prolonging the survival of GC patients.

Citing Articles

Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches.

Prasanth B, Alkhowaiter S, Sawarkar G, Dharshini B, R Baskaran A Cureus. 2024; 15(12):e51090.

PMID: 38274938 PMC: 10808885. DOI: 10.7759/cureus.51090.

Understanding tumour endothelial cell heterogeneity and function from single-cell omics.

Zeng Q, Mousa M, Nadukkandy A, Franssens L, Alnaqbi H, Alshamsi F Nat Rev Cancer. 2023; 23(8):544-564.

PMID: 37349410 DOI: 10.1038/s41568-023-00591-5.

Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models.

Awasthi N, Schwarz M, Kaurich Q, Zhang C, Hilberg F, Schwarz R Front Oncol. 2023; 13:1145999.

PMID: 37234980 PMC: 10206228. DOI: 10.3389/fonc.2023.1145999.

References

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Lopes-Coelho F, Martins F, Pereira S, Serpa J . Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int J Mol Sci. 2021; 22(7). PMC: 8038573. DOI: 10.3390/ijms22073765. View

Gambardella V, Castillo J, Tarazona N, Gimeno-Valiente F, Martinez-Ciarpaglini C, Cabeza-Segura M . The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev. 2020; 86:102015. DOI: 10.1016/j.ctrv.2020.102015. View

Duru G, van Egmond M, Heemskerk N . A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. Front Immunol. 2020; 11:584723. PMC: 7686513. DOI: 10.3389/fimmu.2020.584723. View

Malo C, Khadka R, Ayasoufi K, Jin F, AbouChehade J, Hansen M . Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma. Front Oncol. 2018; 8:320. PMC: 6124655. DOI: 10.3389/fonc.2018.00320. View

Gou M, Zhang Y, Liu T, Qu T, Si H, Wang Z . The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy. Front Oncol. 2021; 11:655716. PMC: 8239234. DOI: 10.3389/fonc.2021.655716. View

Eum H, Kwon M, Ryu D, Jo A, Chung W, Kim N . Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. Exp Mol Med. 2020; 52(12):1976-1988. PMC: 8080575. DOI: 10.1038/s12276-020-00538-y. View

Parisi A, Porzio G, Ficorella C . Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers (Basel). 2020; 12(9). PMC: 7563615. DOI: 10.3390/cancers12092598. View

Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J . Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett. 2021; 21(4):315. PMC: 7933774. DOI: 10.3892/ol.2021.12576. View

10.

Whisner C, Aktipis C . The Role of the Microbiome in Cancer Initiation and Progression: How Microbes and Cancer Cells Utilize Excess Energy and Promote One Another's Growth. Curr Nutr Rep. 2019; 8(1):42-51. PMC: 6426824. DOI: 10.1007/s13668-019-0257-2. View

11.

Chen J, Ren Y, Shu C, Zhang Y, Chen M, Xu J . JP3, an antiangiogenic peptide, inhibits growth and metastasis of gastric cancer through TRIM25/SP1/MMP2 axis. J Exp Clin Cancer Res. 2020; 39(1):118. PMC: 7310436. DOI: 10.1186/s13046-020-01617-8. View

12.

Mortezaee K, Potes Y, Mirtavoos-Mahyari H, Motevaseli E, Shabeeb D, Musa A . Boosting immune system against cancer by melatonin: A mechanistic viewpoint. Life Sci. 2019; 238:116960. DOI: 10.1016/j.lfs.2019.116960. View

13.

Feng Y, Dai Y, Gong Z, Cheng J, Zhang L, Sun C . Association between angiogenesis and cytotoxic signatures in the tumor microenvironment of gastric cancer. Onco Targets Ther. 2018; 11:2725-2733. PMC: 5953302. DOI: 10.2147/OTT.S162729. View

14.

Chen X, Wang H, Huang Y, Chen Y, Chen C, Zhuo W . Comprehensive Roles and Future Perspectives of Exosomes in Peritoneal Metastasis of Gastric Cancer. Front Oncol. 2021; 11:684871. PMC: 8276633. DOI: 10.3389/fonc.2021.684871. View

15.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K . Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019; 12(1):27. PMC: 6417086. DOI: 10.1186/s13045-019-0718-5. View

16.

Ooki A, Yamaguchi K . The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer. 2021; 24(6):1169-1183. DOI: 10.1007/s10120-021-01235-z. View

17.

Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q . Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017; 8(34):57386-57398. PMC: 5593650. DOI: 10.18632/oncotarget.18065. View

18.

Pellino A, Riello E, Nappo F, Brignola S, Murgioni S, Ahcene Djaballah S . Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J Gastroenterol. 2019; 25(38):5773-5788. PMC: 6801189. DOI: 10.3748/wjg.v25.i38.5773. View

19.

Bang Y, Golan T, Dahan L, Fu S, Moreno V, Park K . Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020; 137:272-284. DOI: 10.1016/j.ejca.2020.06.007. View

20.

Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X . Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest. 2018; 128(5):2104-2115. PMC: 5957454. DOI: 10.1172/JCI96582. View